Market Tracker

01/20 5:16pm ET

Myriad Genetics Inc (NASDAQ:MYGN)

15.66
Delayed Data
As of Jan 20
 +0.20 / +1.29%
Today’s Change
15.36
Today|||52-Week Range
41.75
-6.06%
Year-to-Date
Casualty List Has Done Well; Here's the Latest
Jan 18 / GuruFocus News - Paid Partner Content
Why Exact Sciences' Stock Could Go Much Higher
Jan 13 / MotleyFool.com - Paid Partner Content
Why Myriad Genetics, Inc. Stock Dropped 61% in 2016
Jan 13 / MotleyFool.com - Paid Partner Content
Better Buy: Myriad Genetics vs. Exact Sciences
Jan 09 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close15.46
Today’s open15.48
Day’s range15.36 - 15.74
Volume1,541,930
Average volume (3 months)1,460,475
Market cap$1.1B
Dividend yield--
Data as of 4:00pm ET, 01/20/2017

Growth & Valuation

Earnings growth (last year)+58.33%
Earnings growth (this year)-38.80%
Earnings growth (next 5 years)-3.00%
Revenue growth (last year)+4.25%
P/E ratio12.3
Price/Sales2.98
Price/Book1.43

Competitors

 Today’s
change
Today’s
% change
AAAPAdvanced Accelerator...+0.14+0.49%
VIVOMeridian Bioscience ...0.000.00%
QDELQuidel Corp+0.28+1.43%
--Quidel Corp-0.28-1.54%
Data as of 4:00pm ET, 01/20/2017

Financials

Next reporting dateFebruary 7, 2017
EPS forecast (this quarter)$0.24
Annual revenue (last year)$753.8M
Annual profit (last year)$125.3M
Net profit margin16.62%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Mark C. Capone
Executive Vice President-
International Operations
Gary A. King
Corporate headquarters
Salt Lake City, Utah

Forecasts